Wave Life Sciences - WVE Stock Forecast, Price & News

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on Wave Life Sciences from $10.00 to $8.00 in a research note on Friday, May 13th.

Wave Life Sciences Trading Up 17.4 %

WVE traded up $0.52 during trading on Friday, hitting $3.50. The company's stock had a trading volume of 1,179,114 shares, compared to its average volume of 473,194. Wave Life Sciences has a twelve month low of $1.16 and a twelve month high of $6.64. The business's fifty day simple moving average is $2.83 and its 200 day simple moving average is $2.35. The firm has a market capitalization of $214.37 million, a price-to-earnings ratio of -1.51 and a beta of -0.51.

Wave Life Sciences (NASDAQ:WVE - Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.75 million. Wave Life Sciences had a negative net margin of 275.31% and a negative return on equity of 558.73%. As a group, equities research analysts forecast that Wave Life Sciences will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. bought 9,480,052 shares of the firm's stock in a transaction dated Thursday, June 16th. The shares were acquired at an average price of $2.15 per share, for a total transaction of $20,382,111.80. Following the completion of the transaction, the director now directly owns 17,202,009 shares in the company, valued at approximately $36,984,319.35. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 32.20% of the company's stock.